Omega Therapeutics, Inc. - OMGA STOCK NEWS

Omega Therapeutics (Nasdaq: OMGA) reported first-quarter 2022 results, revealing a cash position of $200.8 million. The company is set to submit an Investigational New Drug (IND) application for OTX-2002 targeting MYC-driven hepatocellular carcinoma in the first half of 2022. Recent preclinical data showcased OTX-2002's ability to downregulate MYC oncogene expression, leading to reduced cancer cell viability. R&D expenses rose to $14.2 million from $9.7 million a year prior, while the net loss expanded to $20.2 million, influenced by increased operational costs.

Omega Therapeutics (OMGA) presented preclinical data demonstrating the effectiveness of its Omega Epigenomic Controllers (OEC) in targeting the MYC oncogene, linked to significant cancer mortality. The OEC shows promise as a standalone or combined treatment for non-small cell lung cancer (NSCLC). Key findings indicate that OEC treatment leads to substantial downregulation of MYC mRNA and protein, enhancing apoptosis in cancerous cells while sparing healthy cells. The results will be discussed at the ASGCT Annual Meeting in Washington D.C. on May 18, 2022.

Omega Therapeutics (NASDAQ: OMGA) announced the appointment of Joshua Reed as Chief Financial Officer effective May 23, 2022. Reed brings extensive experience from Aldeyra Therapeutics and Bristol-Myers Squibb, where he managed finance and operations. Current CFO Roger Sawhney, M.D., will transition to Chief Business Officer. This leadership change follows several key hires aimed at enhancing the company's capacity to drive its innovative mRNA-based epigenetic therapies forward. The company remains focused on advancing its pipeline across multiple disease areas.

Tessera Therapeutics has secured over $300 million in Series C financing to advance its GENE WRITING technology aimed at curing genetic diseases. Investors include the Abu Dhabi Investment Authority and Alaska Permanent Fund Corporation. CEO Geoffrey von Maltzahn emphasizes the transformative potential of genetic medicine. The GENE WRITING platform enables precise modifications to DNA, unlocking new treatment possibilities for various conditions. Tessera's innovative approach positions it to potentially lead a new category in genetic medicine.

Omega Therapeutics (NASDAQ: OMGA) announced promising preclinical data for its lead therapeutic candidate, OTX-2002, designed to target the c-Myc oncogene in hepatocellular carcinoma (HCC). The data indicated that OTX-2002 significantly reduced tumor growth in in vivo models and suppressed c-Myc gene expression, leading to a notable loss of cancer cell viability in vitro. The company plans to file an Investigational New Drug application in the first half of 2022 to advance OTX-2002 into clinical trials, showcasing the potential of its OMEGA Epigenomic Programming™ platform.

Omega Therapeutics (Nasdaq: OMGA) announced on March 30, 2022, the appointment of Kevin McManus as Chief Human Resources Officer and Ling Zeng, Esq. as Chief Legal and Administrative Officer. McManus, with extensive experience in organizational development, aims to enhance talent acquisition and company culture. Zeng brings a strong legal background from Dicerna Pharmaceuticals and Novartis. These appointments come as Omega seeks to advance its OMEGA Epigenomic Programming™ platform and scale the company further, indicating a crucial growth phase in their innovative biopharmaceutical journey.

Omega Therapeutics, Inc. (Nasdaq: OMGA) announced its financial results for Q4 and full year 2021, reporting a net loss of $68.3 million, up from $29.4 million in 2020. R&D expenses surged to $47.9 million from $21.1 million, driven by increased development costs. The company announced plans to submit an Investigational New Drug (IND) application for OTX-2002 in H1 2022, targeting c-Myc-driven hepatocellular carcinoma. Financial resources remain strong, with $225.3 million in cash and equivalents as of Dec 31, 2021.

Omega Therapeutics (Nasdaq: OMGA) announced the upcoming presentation of preclinical data for its lead drug candidate OTX-2002, aimed at treating hepatocellular carcinoma (HCC), at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The data showcase the potential of targeting the c-MYC oncogene, linked to aggressive HCC in up to 70% of cases. Omega plans to file an Investigational New Drug application for OTX-2002 later in 2022, signaling progress in their OMEGA Epigenomic Programming™ platform, which seeks to modulate gene expression through innovative mRNA therapeutics.

Cellarity has announced key appointments to its executive team, enhancing its expertise in drug development. Laurens Kruidenier, Ph.D., joins as Chief Scientific Officer to lead drug platform evolution, while Anna O’Driscoll becomes Chief People Officer to drive talent development. Parul Doshi is appointed Senior VP, Head of Data and Software Engineering to bolster data infrastructure. These changes underscore Cellarity's commitment to advancing its drug creation process, particularly its unique approach that examines cellular changes underlying diseases, applicable across multiple therapeutic areas.